Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)

被引：1

作者：

Garcia Campelo, R. ^{[1
]}

Lin, H. ^{[2
]}

Perol, M. ^{[3
]}

Jahanzeb, M. ^{[4
]}

Popat, S. ^{[5
,6
]}

Zhu, Y. ^{[2
]}

Zhang, P. ^{[2
]}

Camidge, D. R. ^{[7
]}

机构：

[1] Univ Hosp A Coruna Xxiac Sergas, Med Oncol Serv, La Coruna, Spain

[2] Millennium Pharmaceut Inc, Cambridge, MA USA

[3] Ctr Leon Berard, Dept Thorac Oncol, Lyon, France

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Deerfield Beach, FL USA

[5] Royal Marsden Hosp, London, England

[6] Imperial Coll London, Natl Heart & Lung Inst, London, England

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

关键词：

brigatinib; Health-related quality of life; Non-small cell lung cancer;

D O I：

10.1016/j.jtho.2019.08.839

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-124

引用

页码：S411 / S412

页数：2